The consequence of p53 overexpression for liver tumor development and the response of transformed murine hepatocytes to genotoxic agents
- 20 July 2000
- journal article
- Published by Springer Nature in Oncogene
- Vol. 19 (31), 3498-3507
- https://doi.org/10.1038/sj.onc.1203671
Abstract
To analyse the effect of p53 on liver tumor development, we generated transgenic mice overexpressing wild-type p53 in the liver and crossed them with transgenic mice in which the expression of the SV40 large T antigen (TAg) induces hepatic tumors. Remarkably, whereas preneoplastic TAg liver exhibited anisocaryosis and anisocytosis, TAg/p53 liver never presented any dysplastic cells. Moreover, whereas expression of p53 did not affect hepatic development, its constitutive expression in tumorigenic livers resulted in a significantly enhanced apoptosis once nodules had appeared. In contrast, p53 overexpression did not modify the elevated proliferation of TAg-transformed hepatocytes and had no effect on hepatocarcinoma progression. In vitro analysis of primary hepatocytes exposed to various genotoxic agents showed that p53 failed to sensitize normal or TAg-transformed hepatocytes to apoptosis, except when high doses of doxorubicin, UV-B and UV-C radiation were used. Our results confirmed that the hepatocyte cell type is very resistant to genotoxic agents and showed that constitutive expression of p53 failed to improve their responsiveness. In addition, our results showed that suppression of dysplastic cells, probably by restoring normal cytokinesis and karyokinesis, and enhancement of apoptosis by means of p53 overexpression were insufficient to counteract or delay the TAg-induced liver tumoral progression. Oncogene (2000) 19, 3498 - 3507Keywords
This publication has 45 references indexed in Scilit:
- Testicular wild-type p53 expression in transgenic mice induces spermiogenesis alterations ranging from differentiation defects to apoptosisOncogene, 1999
- Prevention of mammalian DNA reduplication, following the release from the mitotic spindle checkpoint, requires p53 protein, but not p53-mediated transcriptional activityOncogene, 1998
- Association of Loss of Heterozygosity at the p53 Locus with Chemoresistance in OsteosarcomasJapanese Journal of Cancer Research, 1998
- A transgenic mouse model for mammary carcinogenesisOncogene, 1998
- Transgenic mice with p53-responsive lacZ: p53activity varies dramatically during normal development and determines radiation and drug sensitivity invivoThe EMBO Journal, 1997
- CANCER BIOLOGY: Drug-resistant breast cancer cells frequently retain expression of a functional wild-type p53 proteinCarcinogenesis: Integrative Cancer Research, 1996
- p53, guardian of the genomeNature, 1992
- The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivationCell, 1992
- Time-course development of differentiated hepatocarcinoma and lung metastasis in transgenic miceJournal of Hepatology, 1991
- The p53 tumour suppressor geneNature, 1991